

# SEPT 2022

Lille | Faculté de Médecine - Pôle Recherche | 14-16 juin

## PROGRAMME

Congrès de la Société Française  
de Pharmacologie et de Thérapeutique



Société Française de  
Pharmacologie et de Thérapeutique



# sommaire

SOCIÉTÉS ET COMITÉS .....	04
MOT DE BIENVENUE .....	05
PROGRAMME EN UN COUP D'ŒIL .....	06
PROGRAMME SCIENTIFIQUE .....	08
• Mardi 14 juin .....	08
• Mercredi 15 juin .....	18
• Jeudi 16 juin .....	26
LISTE DES E-POSTERS SIMPLES (PS) .....	28
INFORMATIONS PRATIQUES .....	34
PLAN DU PÔLE RECHERCHE .....	36
NOTES .....	38
REMERCIEMENTS .....	42



# SOCIÉTÉS & COMITÉS

## CONSEIL D'ADMINISTRATION

**Dominique DEPLANQUE** (Président)  
**Pierre-François DEQUIN** (Vice-Président)  
**Frédéric LIBERT** (Trésorier)  
**Nicolas PICARD** (Secrétaire Général)

Laurent BERTOLETTI  
Pascal BOUSQUET  
Jean-Luc CRACOWSKI  
Céline DEMOUGEOT  
Sébastien FAURE  
Véronique LAMARQUE-GARNIER  
Mathieu MOLIMARD  
Jean-Louis MONTASTRUC  
Stéphane MOULY  
Catherine OIRY-CUQ  
Antoine PARIENTE  
Luc ZIMMER (Président CS)

## CONSEIL SCIENTIFIQUE

**Luc ZIMMER** (Président)  
**Matthieu ROUSTIT** (Vice-Président)  
**Caroline VICTORRI-VIGNEAU** (Vice-Présidente)

Mathieu CHARVERIAT  
Dominique DEPLANQUE (Président CA)  
Charles DOLLADILLE  
Véronique LEBLAIS  
Jean-Christophe LEGA  
Florian LEMAITRE  
Patrick ROSSIGNOL  
Françoise STANKE-LABESQUE

## COMITÉ LOCAL D'ORGANISATION

**Régis BORDET**  
**Dominique DEPLANQUE**  
**Marc LAMBERT**  
**Sophie GAUTIER**  
**David DEVOS**  
**Louise CARTON**

Thavarak OUK  
Raphaël FAVORY  
Cécile YELNIK  
Karim BELARBI  
Thierry DINE  
Bernard GRESSIN

## SECRÉTARIAT DE LA SFPT

**Florence GUENAND**



## Mot de Bienvenue

Notre congrès de la SFPT à Lille, initialement prévu en 2020, va bien avoir lieu, enfin. Cette réunion de notre communauté se placera sous le double signe de l'international et de l'interactivité...

En effet, nous profiterons de la position géographique de Lille pour inviter des conférenciers étrangers qui mêleront leurs expertises à celles des pharmacologues et thérapeutes français. Notre priorité reste de favoriser l'interactivité entre les disciplines de la pharmacologie et de la thérapeutique :

- À travers un symposium sur les interactions pluridisciplinaires autour du bon usage médicamenteux ;
- Au cours de tables rondes liées à des sujets d'actualité du médicament, voire des controverses ;
- Dans la présentation des posters avec un système connecté interactif ;
- Par la simulation interactive au cours du DPC ;
- Et même au cours de la soirée de gala...

Personne ne sera surpris qu'une large place soit faite à la neuro-psychopharmacologie, mais pas uniquement. Ainsi, nous porterons un coup de projecteur sur les innovations thérapeutiques dans le champ des hémopathies et sur une nouvelle forme de mort cellulaire, la ferroptose. Ouverture, innovation, transversalité seront réunies pour que le congrès de Lille concilie une vision collective du médicament et la convivialité des gens du Nord !

Et puisque ce mot est également l'occasion de marquer le passage de flambeau de la présidence du conseil scientifique de la SFPT à Luc, laissons le soin à notre hôte Régis de conclure :

*"Viendez les tiots biloutes, restez pont al'cour car on veut pont donner d'eul'confiture à des pourchiots!"*

**Régis Bordet  
Luc Zimmer**

**Ex-Président et Président du conseil scientifique de la SFPT**

# PROGRAMME EN UN COUP D'ŒIL

## MARDI 14 JUIN

A partir de 10h00	Accueil des participants <span style="background-color: orange; color: white; padding: 2px;">Salle du Conseil</span>					 <p>Journée des CIC 10h00-16h00 <b>Inserm</b> La science pour la santé From science to health</p>		
10h30 - 12h00	Groupe STP-PT <span style="background-color: orange; color: white; padding: 2px;">Salle des Thèses</span>	Groupe REVISE <span style="background-color: orange; color: white; padding: 2px;">Salle 1</span>	Groupe Neuropsychopharmacologie <span style="background-color: orange; color: white; padding: 2px;">Salle 2</span>	Réseau AVENIR <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>	Groupe Pharmaco-épidémiologie <span style="background-color: orange; color: white; padding: 2px;">Salle 4</span>			
12h05	Ouverture du congrès <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>							
12h00 – 12h15	Déjeuner - Lunch Box <span style="background-color: orange; color: white; padding: 2px;">Atrium + Hall d'accueil</span>							
12h15 - 13h15	Symposium Partenaire <b>ThermoFisher SCIENTIFIC</b> <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>							
13h30 - 15h00	Actualités sur le médicament et actualités thérapeutiques <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>	Pharmacologie moléculaire et pré-clinique <span style="background-color: orange; color: white; padding: 2px;">Salle des Thèses</span>	Pharmacosurveillance – Pharmacovigilance <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>					
15h00 - 16h30	Happy Hour Posters (modérés PM1 + e-posters simples) <span style="background-color: orange; color: white; padding: 2px;">Atrium + Hall d'accueil</span> Pause-café							
16h30 - 18h00	Pharmacologie clinique, méthodologie <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>	Neuropsychopharmacologie <span style="background-color: orange; color: white; padding: 2px;">Salle des Thèses</span>	Pharmacologie cardiovasculaire <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>					
18h00 - 19h30	Réunion CNET <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>	Réunion AEPFP <span style="background-color: orange; color: white; padding: 2px;">Salle des Thèses</span>	Réunion CNPM <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>					

## MERCREDI 15 JUIN

08h30 - 09h30	Communications libres Thème Pharmaco-épidémiologie <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>	Communications libres Thème Populations particulières <span style="background-color: orange; color: white; padding: 2px;">Salle des Thèses</span>	Communications libres Thème Pharmacosurveillance - Addictovigilance <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>		
09h30 – 10h00	Prix de thèse – Ma thèse en 180 secondes <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>				
10h00 - 11h00	Happy Hour Posters (modérés PM2 + e-posters simples) - Pause-café <span style="background-color: orange; color: white; padding: 2px;">Atrium + Hall d'accueil</span>				
11h00 - 12h30	Thème transversal 1 : Nouvelles approches / interventions dans les hémopathies malignes <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>		Débat / Table ronde : Nouvelles procédures accélérées de mise sur le marché de médicaments, prise de risque ou progrès? <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>		
12h30 - 13h45	Déjeuner - Lunch Box <span style="background-color: orange; color: white; padding: 2px;">Atrium + Hall d'accueil</span>				
12h45 - 13h45	Symposium partenaire <b>promise ADVANCED PROTEOMICS</b> <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>	Symposium partenaire <b>Pfizer</b> <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>			
14h00 - 15h30	Thème transversal 2 : Pharmacologie des troubles cognitifs <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>				
15h30 - 16h00	Rendez-vous e-posters simples - Pause-café <span style="background-color: orange; color: white; padding: 2px;">Atrium + Hall d'accueil</span>				
16h00 - 17h30	Thème transversal 2 : Pharmacologie des troubles cognitifs <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>				
17h30 - 18h30	STP, Modélisation Bioéquivalence et variabilité : un nouveau chapitre ? <span style="background-color: orange; color: white; padding: 2px;">Amphi A</span>	Communications libres Thème Covid <span style="background-color: orange; color: white; padding: 2px;">Salle des Thèses</span>	Table ronde pharmacologues, cliniciens, patients, media : tous ensemble lanceurs d'alerte <span style="background-color: orange; color: white; padding: 2px;">Amphi Congrès</span>		
19h30	Soirée du congrès (sur inscription) <span style="background-color: green; color: white; padding: 2px;">Salle KINO – Domaine universitaire Pont de Bois – Villeneuve d'Ascq</span>				



## JEUDI 16 JUIN

09h00 - 10h30	Thème transversal 4 : Pharmacologie de la ferroptose  <span style="background-color: orange; border: 1px solid black; padding: 2px;">Amphi A</span>	Communications libres Thème STP  <span style="background-color: orange; border: 1px solid black; padding: 2px;">Salle des Thèses</span>	Thème transversal 3 : Le médicament, un objet d'interactions  <span style="background-color: orange; border: 1px solid black; padding: 2px;">Amphi Congrès</span>
10h30 – 11h00	Pause-café  <span style="background-color: orange; border: 1px solid black; padding: 2px;">Atrium + Hall d'accueil</span>		
11h00 - 12h00	Assemblée Générale de la SFPT et remise des prix  <span style="background-color: orange; border: 1px solid black; padding: 2px;">Amphi Congrès</span>		
12h00 - 12h30	Déjeuner - Lunch box  <span style="background-color: orange; border: 1px solid black; padding: 2px;">Atrium + Hall d'accueil</span>		
12h30 -15h30	<span style="background-color: orange; border: 1px solid black; padding: 2px; font-size: small;">Salle Présage</span> <b>Atelier DPC n°65952200002</b> Chambre des erreurs : améliorer la qualité et la sécurité des soins et du patient par la mise en situation	<span style="background-color: orange; border: 1px solid black; padding: 2px; font-size: small;">Salle 4</span> <b>Atelier DPC n°65952200001</b> <b>Bon usage des psychotropes :</b> comment optimiser la prescription	<span style="background-color: orange; border: 1px solid black; padding: 2px; font-size: small;">Amphi A</span> <b>Atelier Expérimentation animale</b> Exploration comportementale et neuroimagerie

# PROGRAMME SCIENTIFIQUE

## MARDI 14 JUIN

**10h30 - 12h00**

- > Groupe STP-PT : Apport de nos travaux sur la pratique en Pharmacologie Biologique

10h30 – 12h00 **SALLE DES THÈSES**

- > Groupe de travail REVISE : Impact des nouveaux Règlements Européens sur la conduite et la sécurité des essais cliniques

10h30 – 12h00 **SALLE 1**

- > Groupe de travail Neuropsychopharmacologie

10h30 – 12h00 **SALLE 2**

- > Session du Réseau Avenir spéciale éloquence : ouverte à tous

10h30 – 12h00 **AMPHI CONGRÈS**

- > Groupe Pharmaco-épidémiologie

10h30 – 12h00 **SALLE 4**

**12h05 – 12h15 AMPHI CONGRÈS**

- > Ouverture du congrès

**12h15 – 13h15 AMPHI A**

- > Symposium THERMO FISHER : Personnalisation des traitements dans les populations vulnérables : modèle du patient greffé **ThermoFisher SCIENTIFIC**

- Modérateur : Docteur Romain GUILHAUMOU, AP-HM (Marseille)
- Aspects Cliniques : Professeur Sébastien DHARANCY, CHU Lille
- Aspects Pharmacologiques : Docteur Caroline MONCHAUD, CHU Limoges
- Aspects Analytiques : Professeur Frédéric COTTON, LHUB-ULB, Bruxelles
- Discussion

**13h30 – 15h00 AMPHI A**

- > Actualités sur le médicament et actualités thérapeutiques

- Modérateurs: Florian NAUDET (Rennes), Claire DEMIOT (Limoges)

Conférence invitée

- 13h30 Nouvelles recommandations thérapeutiques pour les douleurs neuropathiques : vers de nouvelles pratiques ? Nadine ATTAL (Paris)



### Communications libres

- 14h00 ACT-001 - Is there still a place for methotrexate in severe psoriatic arthritis?  
Renaud FELTEN (Strasbourg)
- 14h10 ACT-002 - Improving availability of naloxone: an emergency - Aurélie AQUIZERATE (Nantes)
- 14h20 ACT-003 - National pharmacovigilance surveillance of AstraZeneca Covid-19 vaccine (ChAdOx1-S vaccine) - Nathalie MASSY (Rouen)
- 14h30 ACT-004 - Recommendations of the French Society of Rheumatology and the French Society of Physical Medicine and Rehabilitation on the non-pharmacological management of knee osteoarthritis - Yves-Marie PERS (Montpellier)
- 14h40 ACT-005 - Management of drug-drug interactions with Nirmatrelvir/Ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) - Florian LEMAITRE (Rennes)
- 14h50 ACT-006 - Adverse events associated with JAK inhibitors - Emilie SBIDIAN (Créteil)

### **13h30 - 15h00 SALLE DES THÈSES**

#### **> Pharmacologie moléculaire et pré-clinique**

- Modérateurs : Véronique LEBLAIS (Paris), Nicolas CLÈRE (Angers)

### Conférence invitée

- 13h30 Phosphodiesterase et modulation pharmaco - Boris MANOURY (Chatenay-Malabry)

### Communications libres

- 14h00 CO-001 - Impact of the new CFTR modulators treatment on the respiratory epithelium.  
Emmanuelle BARDIN (Paris)
- 14h10 CO-002 - Pharmacokinetics study showed increased brain delivery of anti-PD-1 after ultrasound-mediated blood-brain barrier in glioblastoma mouse models - Noël ZAHR (Paris)
- 14h20 CO-003 - TP53-mutant selection by MDM2 inhibition: single cell analysis and predictive assay - Nabih MASLAH (Paris)
- 14h30 CO-004 - Modulation of HCN channel activity in oxaliplatin-induced peripheral neuropathy - Margaux MOREZ (Clermont-Ferrand)
- 14h40 CO-005 - Neuroprotective effect of hlg in mouse models of chemotherapy-induced neuropathy - Mohamad MROUE (Limoges)

# PROGRAMME SCIENTIFIQUE

**13h30 - 15h00 AMPHI CONGRÈS**

## > Pharmacosurveillance - Pharmacovigilance

- Modératrices : Marion LEPELLEY (Grenoble), Sophie GAUTIER (Lille)

### Conférence invitée

- 13h30 Quel impact de la crise sanitaire sur la détection et l'analyse du signal en Pharmacovigilance ? Annie-Pierre JONVILLE-BERA (Tours) et Céline MOUNIER, ANSM (Paris)

### Communications libres

- 14h00 CO-007 - Nonsteroidal anti-inflammatory drugs exposure in complicated acute community-acquired bacterial infections, a French multicentre case-control study (ANAIG) - Gwenaëlle VEYRAC (Nantes)
- 14h10 CO-008 - Latrogenic consequences of drug shortage: the CIRUPT Study from the French Network of Regional Pharmacovigilance Centers - Delphine BOURNEAU-MARTIN (Angers)
- 14h20 CO-009 - Lack of therapeutic efficacy: a picture of notified cases to the French PV network - Marie-Blanche VALNET RABIER (Besançon)
- 14h30 CO-010 - 3 M syndrom (Myasthenia myositis myocarditis) related to nivolumab treatment - Frank ROUBY (Marseille)
- 14h40 CO-011 - Lamotrigine associated serotonin syndrome: analysis of the reports in VigiBase® - Basile CHRÉTIEN (Caen)
- 14h50 CO-012 - Associations between Th1-mediated diseases and omalizumab: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®) - Benjamin BATTEUX (Amiens)



## 15h00 – 16h30 Happy Hour Posters (PM1)

atrium + hall d'accueil

### ZONE JAUNE Préclinique

Modérateurs: Boris MANOURY (Chatenay-Malabry), Mélina BEGOU (Clermont-Ferrand)

- PM1-001 - Effect of local ice cryotherapy on aortic inflammation and endothelial activation in rat adjuvant-induced arthritis - Perle TOTOSON (Besançon)
- PM1-002 - Lack of protective effect of CCR3 blockade during experimental colitis may be related to CCR3 expression by colonic Tregs - Jean-Yves JOUZEAU (Vandoeuvre-lès-Nancy)
- PM1-003 - Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis - Jean-Yves JOUZEAU (Vandoeuvre-lès-Nancy)
- PM1-005 - Synovial tissue and systemic pharmacokinetics of rapamycin-loaded nanoparticles versus free rapamycin for articular vectorization in rat knee - Elise PAPE (Nancy)
- PM1-006 - Effect of glucocorticoids on intestinal permeability, epithelial damage and bacterial translocation in rat adjuvant-induced arthritis - Céline DEMOUGEOT (Besançon)
- PM1-007 - Influence of stress on [<sup>18</sup>F]F13640 binding, a 5-HT1A receptor agonist used as a PET radiopharmaceutical - Pierre COURAULT (Bron)
- PM1-008 - Use of Monte Carlo simulation to prevent pharmacokinetics impairment of amiodarone under VV ECMO - Claire PRESSIAT (Créteil)

### ZONE VERTE Pharmacologie clinique

Modérateurs: Edouard OLLIER (Saint-Priest-en-Jarez), Mikail NOURREDINE (Lille)

- PM1-009 - Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach - Renaud FELTEN (Strasbourg)
- PM1-010 - Development of new tacrolimus C0-based metrics and their association with new onset diabetes mellitus in renal transplant patients - Alexandre DESTERE (Nice)
- PM1-011 - Alteration of the gastrointestinal epithelium in transplant patients under mycophenolic acid therapy - Clarisse BROSSIER (Limoges)
- PM1-012 - Pharmacological data of a successful short cycle therapy (ANRS QUATUOR Trial) - Emuri ABE (Garches)
- PM1-013 - Use of amoxicillin/clavulanate in severe alcoholic hepatitis: preliminary safety data from the Antibiocor-HAA study - Camille POTEY (Lille)
- PM1-014 - Clinical trials in times of pandemic: adapting without losing quality (2/2). Construction of a collaborative international meta-trial. Pierre-François DEQUIN (Tours)
- PM1-015 - Daptomycin efficacy and safety for treatment of Gram positive infections: a systematic review and meta-analysis - Jean-Christophe LEGA (Lille)
- PM1-016 - The conservative iron chelation in Parkinson's disease, preliminary safety data about hematological tolerance from the FAIR-PARK II study - Céline LECLERCQ (Lille)

# PROGRAMME SCIENTIFIQUE

## 15h00 – 16h30 Happy Hour Posters (PM1)

atrium + hall d'accueil

### ZONE ROSE STP 1

Modérateurs : Peggy GANDIA (Toulouse),  
Youssef BENNIS (Amiens)

- PM1-017 - Ciprofloxacin population pharmacokinetics during long term treatment of osteoarticular infections - Noël ZAHR (Paris)
- PM1-018 - Blood, cellular and tissular cyclosporine pharmacokinetic-pharmacodynamic relationship in heart transplant recipients: preliminary results of the INTRACAR study - Florian LEMAITRE (Rennes)
- PM1-019 - An easy, fast and inexpensive multiplex pharmacogenetics assay to simultaneously analyze 17 clinically relevant genetic polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1 and VKORC1 genes - Camille TRON (Rennes)
- PM1-020 - Comparison of equilibrium dialysis and ultrafiltration to measure unbound plasma concentrations of cefazolin - Sarah BAKLOUTI (Toulouse)
- PM1-021 - A physiology-based pharmacokinetic model (PBPK) to study daptomycin penetration into bone tissue. - Laurent BOURGUIGNON (Lille)
- PM1-022 - Investigation of O-demethyl tramadol / tramadol ratio for cytochrome P450 2D6 phenotyping: the CYTRAM study - Soizic PERCEVAULT (Lille)
- PM1-023 - Benchmarking the posologyR package, a free software for model-informed precision dosing: extensive validation of Maximum A Posteriori estimates of pharmacokinetic parameters against NONMEM - Camille MANÉ (Brest)
- PM1-024 - Amiodarone/N-desethylamiodarone population pharmacokinetics in pediatric patients - Naïm BOUAZZA (Paris)

### ZONE GRISE Pharmacovigilance 1

Modérateurs : Elisabeth POLARD (Rennes),  
Laurent CHOUCANA (Paris)

- PM1-025 - Immune checkpoint inhibitors induced liver injury: an observational study - Pascale PALASSIN (Montpellier)
- PM1-026 - Evolution of adverse drug reactions with aprotinin reported in Vigibase® over time - Clémence HUYNH (Bordeaux)
- PM1-027 - Adverse drug reactions of carfilzomib: study in the French Pharmacovigilance Database - Killian FARLAN (Paris)
- PM1-029 - OFF label use in Burgundy-Franche Comte region: an overview of the practices to improve the public health messages - Marie-Blanche VALNET RABIER (Besançon)
- PM1-030 - Clinical Trials: Nature and Impact of New Safety Information reported between 2017 and 2021 by Vigilance Unit of Rennes University Hospital - Catherine MOUCHEL (Rennes)
- PM1-031 - Impact of vaccine hesitancy on onset and severity of adverse events - Ayoub LARABI (Grenoble)



**ZONE BLEUE**  
**Addictovigilance 1**

Modératrices : Hélène PEYRIERE (Montpellier),  
Elisabeth FRAUGER (Marseille)

- PM1-032 - Antidotes use in plants self-poisoning: a 20-years-retrospective of the Marseille poison control center - Romain TORRENTE (Marseille)
- PM1-033 - Trend of New Psychoactive Substances use in Paris metropolis highlighted by hair testing in a cohort of hospitalized patients - Islam Amine LARABI (Garches)
- PM1-034 - Psychoactive substance use by French pregnant women: what can we learn from the oppidum data? - Camille PONTE (Toulouse)
- PM1-035 - The prevalence and determinants of psychoactive substance use among students at the Faculty of Medicine and Pharmacy of Casablanca in Morocco - Imane RAHMOUNE (Casablanca)
- PM1-036 - Oral analgesic consumption in sickle cell disease patients: data from the French largest panel of patients, PHEDRE study - Marie GÉRARDIN (Nantes)
- PM1-037 - Different profiles of drug use among music festival attendees: first results of the French OCTOPUS study - Caroline VICTORRI-VIGNEAU (Nantes)
- PM1-038 - Hospitalisations related to psychoactive substance intoxication in young adults during and after the first lockdown in Bordeaux Teaching Hospital - Justine PERINO (Bordeaux)

**ZONE VIOLETTE**  
**Psychotropes**

Modérateurs : Louise CARTON (Lille),  
François MONTASTRUC (Toulouse)

- PM1-039 - How to deprescribe esketamine in resistant depression? A discussion of clinical pharmacology - Tanguy TAILLEFER DE LAPORTALIÈRE (Toulouse)
- PM1-040 - Continuous subcutaneous apomorphine infusion for the management of Parkinson's disease at the end-of-life - Matthieu BÉREAU (Besançon)
- PM1-041 - Descriptive analysis of the regulatory change in prescribing and dispensing arrangements for zolpidem in France: Data from the French health insurance and Vigibase® - Claire BERNARDEAU (Caen)
- PM1-042 - Risk of gestational hypertension in women treated with serotonin and norepinephrine reuptake inhibitors: a comparative study in the EFEMERIS database - Christine DAMASE-MICHEL (Toulouse)
- PM1-043 - Overview of changes in the use and abuse of benzodiazepines in the last decade - Thomas SOEIRO (Marseille)
- PM1-044 - What impact of the Covid-19 crisis on the consumption of psychotropic medications in the French region of Pays de la Loire? Edouard-Jules LAFORGUE (Nantes)
- PM1-045 - Clozapine, a too late prescription: trajectories of antipsychotic treatments in patients with schizophrenia before starting clozapine - Edouard-Jules LAFORGUE (Nantes)

# PROGRAMME SCIENTIFIQUE

**16h30 - 18h00 AMPHI A**

## > Pharmacologie clinique, méthodologie

- Modératrices : Silvy LAPORTE (Saint-Etienne), Théodora BEJAN-ANGOULVANT (Tours)

### Conférence invitée

16h30 Comparaison généralisée par paires - Marc BUYSE (Louvain, Belgique)

### Communications libres

17h00 CO-013 - Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis - Sivem AFACH (Créteil)

17h10 CO-014 - Methodological issues in clinical trials assessing treatments in Raynaud's Phenomenon: placebo response and regression towards the mean - Matthieu ROUSTIT (Grenoble)

17h20 CO-015 - Antihypertensive drug treatment alters the prognostic impact of blood pressure measured on treatment - Guillaume GRENET (Lille)

17h30 CO-016 - Clinical trials in times of pandemic: adapting without losing quality (1/2). Embed a COVID-19 group in an ongoing trial - Pierre-François DEQUIN (Tours)

17h40 CO-017 - Adoptive immunotherapy with antiviral CTL infusion: French clinical and virological safety survey - Nadine PETITPAIN (Vandoeuvre-lès-Nancy)

17h50 CO-018 - Model-based network meta-analysis of the dose-response relationship of dexamethasone as adjuvant for locoregional anesthesia - Edouard OLLIER (Saint-Priest-en-Jarez)

**16h30 - 18h00 SALLE DES THÈSES**

## > NeuroPsychoPharmacologie

- Modérateurs : Luc ZIMMER (Lille), David DEVOS (Lille)

### Conférence invitée

16h30 A new way for drug development in neuropsychopharmacology - Michael SPEDDING, IUPHAR (Paris)

### Communications libres

17h00 CO-019 - The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in a cohort of depressed patients - Kenneth CHAPPELL (Le Kremlin-Bicêtre)

17h10 CO-020 - Plasma acetyl-L-carnitine and L-carnitine in major depressive episodes: a case-control study before and after treatment - Abd El Kader AIT TAYEB (Le Kremlin-Bicêtre)

17h20 CO-021 - Plasma concentration of delta9-tetrahydrocannabinol (THC) and its metabolites and clinical features observed after accidental exposure to cannabis in infants and young children: French addictovigilance data - Camille PONTE (Toulouse)

- 17h30 CO-022 - Does concomitant ethanol and diazepam use modulate age-related cognitive decline? Louise CARTON (Lille)
- 17h40 CO-023 - Positive perception of a regulation is associated with a change in practice: the example of zolpidem prescription after its new regulation among French general practitioners - Edouard-Jules LAFORGUE (Nantes)
- 17h50 CO-024 - fMRI exploration of a biased agonist of 5-HT1A receptors to treat levodopa-induced dyskinesia in hemiparkinsonian rats - Sarah CHAIB (Lille)

## 16h30 - 18h00 AMPHI CONGRÈS

### > Pharmacologie cardiovasculaire

- Modérateurs: Jérémie BELLIEN (Rouen), Laurent BERTOLETTI (Saint-Etienne)

#### Conférence invitée

- 16h30 Pharmacology of the clot: towards improved thrombolysis in ischemic stroke - Simon DE MEYER (Louvain, Belgique)

#### Communications libres

- 17h00 CO-025 - Risk of first ischemic stroke and use of antidopaminergic antiemetics: a nationwide case-time-control study - Antoine PARIENTE (Bordeaux)
- 17h10 CO-026 - Gabapentinoid-induced peripheral edema and acute heart failure: a translational approach combining a nationwide pharmacovigilance study with preclinical experimental data - Bérenger LARGEAU (Tours)
- 17h20 CO-027 - Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the french healthcare insurance database - Laëtitia GOSSELIN (Paris)
- 17h30 CO-028 - Inhibiting the phosphatase activity of soluble epoxide hydrolase reduces arterial calcification and prevents the cardiovascular complications of chronic kidney disease - Hind MESSAOUDI (Rouen)
- 17h40 CO-029 - Heart valves penetration of amoxicillin in infective endocarditis patients: first results from the BELADIFF study - Sébastien LALANNE (Rennes)
- 17h50 CO-030 - Do 5-HT2B receptor agonists that recruit beta-arrestin 2 induce valvulopathy ? Estelle AYME-DIETRICH (Strasbourg)

## 18h00 - 19h30 AMPHI A

### > Réunion CNET

## 18h00 - 19h30 SALLE DES THÈSES

### > Réunion AEPFP

## 18h00 - 19h30 AMPHI CONGRÈS

### > Réunion CNPM

# PROGRAMME SCIENTIFIQUE



**MARDI 14 JUIN**



La science pour la santé  
From science to health

## XII<sup>e</sup> Journée annuelle du réseau national des CIC

AMPHI D

**09h00 - 10h00**

> Accueil café

**10h00**

- Ouverture : Hélène Espérou et Dominique Deplanque
- Président de séance : Lionel Pazart

**10h10**

> Conférences

- Acteurs de l'intégrité scientifique : Office français de l'intégrité scientifique, délégation à l'intégrité scientifique, réseau national RESINT, programme Lorier...  
*Ghislaine Filliatreau, délégation à l'intégrité scientifique (DIS) de l'Inserm*
- La zone grise de l'intégrité : pratiques questionnables et gaspillage en recherche  
*Behrouz Kassai, CIC de Lyon*
- Crise de la reproductibilité : exemples dans le domaine médical, piste de solution  
*Florian Naudet, CIC de Rennes*
- Discussion avec les participants

**11h30**

- Development of computer modeling and in silico models in the field of clinical research  
*Liesbet Geris, Virtual Physiological Human Institute, Belgique*
- Recherche Vaccinale - Covid 19  
*Odile Launay, CIC de Cochin, responsable du réseau I-Reivac et de la plateforme COVIREIVAC*

**12h30 - 14h00**

> Pause déjeuner

- Président de séance : Bruno Laviolle

## 14h00

### > Activités transversales

- Bilan et travaux du Réseau Quali-CIC  
*Claire Thalamas, CIC de Toulouse*

## 14h30

### > Projets

- La ventilation en réanimation : de la recherche physiologique aux grands essais cliniques,  
*Arnaud Thille, CIC de Poitiers*
- PREMANDYSK : Impact de l'association précoce de l'amantadine à la L-DOPA  
sur les dyskinésies dans la maladie de Parkinson  
*Olivier Rascol, réseau NS-Park-FCRIN*
- Etude pilote "MucoExocet" : évaluation de l'utilisation des objets connectés pour la détection précoce et le traitement des exacerbations des patients atteints de mucoviscidose  
*Enora Le Roux, CIC de Robert Debré*
- Rôle des CIC dans la conduite d'essais dans les maladies rares : exemple des essais dans le syndrome de CLOVES.  
*Maxime Luu, CIC de Dijon*

## 16h00

### > Clôture

# PROGRAMME SCIENTIFIQUE



## MERCREDI 15 JUIN

### 08h30 - 09h30 AMPHI A

#### > Communications libres - Thème Pharmaco-épidémiologie

- Modérateurs: Antoine PARIENTE (Bordeaux), Lucie-Marie SCAILTEUX (Rennes)

##### Communications libres

- 08h30 CO-031 - Risk of suicidal behavior associated with benzodiazepines: a nationwide case-crossover study - Antoine PARIENTE (Bordeaux)
- 08h40 CO-032 - Risk of hospitalization for vaso-occlusive episode after exposure to systemic corticosteroids in patients with sickle cell disease - Margaux LAFaurie (Toulouse)
- 08h50 CO-033 - Impact of cardiovascular comorbidities on the effectiveness and safety of bevacizumab in older patients with metastatic colorectal cancer - Pernelle NOIZE (Bordeaux)
- 09h00 CO-034 - Drug-related risks and immune thrombocytopenia, a pharmacoepidemiological approach of three issues - Margaux LAFaurie (Toulouse)
- 09h10 CO-035 - National ranking of prescription drug abuse in the general population using doctor shopping behavior - Thomas SOEIRO (Marseille)
- 09h20 CO-036 - Drug shortage management in community pharmacies and patient safety - Geneviève DURRIEU (Toulouse)

### 08h30 - 09h30 SALLE DES THÈSES

#### > Communications libres - Thème Populations particulières

- Modérateurs: Behrouz KASSAI (Lille), Zoubir DJERADA (Reims)

##### Communications libres

- 08h30 CO-037 - Implementation of a vancomycin dose-optimization protocol in neonates: impact on vancomycin exposure, biological parameters, and clinical outcomes - Françoise STANKE-LABESQUE (Grenoble)
- 08h40 CO-038 - Cost of potentially inappropriate prescriptions in older adults in France - Marie-Laure LAROCHE (Limoges)
- 08h50 CO-039 - Maternal antidepressant use in pregnancy and major birth defects - Laurent CHOUCANA (Paris)
- 09h00 CO-040 - Evaluation of renal impairment influence on cytochrome enzyme activity by a modelling approach - Vianney TULOUP (Lille)
- 09h10 CO-041 - Fetal adverse drug reactions with biologic Disease Modifying Anti-Rheumatic Drugs used during pregnancy: insights from a World Health Organization pharmacovigilance database study (VigiBase®) - Benjamin BATTEUX (Amiens)
- 09h20 CO-042 - Prednisolone pharmacokinetics after oral prednisone administration in pediatric patients with kidney transplant - Naïm BOUAZZA (Paris)

## 08h30 - 09h30 AMPHI CONGRÈS

### > Communications libres - Thème Pharmacosurveillance - Addictovigilance

- Modératrices: Sylvie DEHEUL (Lille), Caroline VICTORRI-VIGNEAU (Nantes)

#### Communications libres

- 08h30 CO-043 - The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database - Marion ROBERT (Grenoble)
- 08h40 CO-044 - Knowledge and diffusion of take-home naloxone among people who use opioids - Salim MEZAACHE (Marseille)
- 08h50 CO-045 - What are the psychoactive substances consumed intravenously? 11 years of observation through the national program OPPIDUM - Clémence LACROIX (Marseille)
- 09h00 CO-046 - Opioid cough suppressants: update addictovigilance data - Valérie GIBAJA (Nancy)
- 09h10 CO-047 - An overview of the use of psychoactive substances among students at the University of Lille - Axel BASTIEN (Lille)
- 09h20 CO-048 - Cross-sectional study of the prevalence of opioids misuse in French patients with chronic non-cancer pain: an update with the French version of POMI scale - Noémie DELAGE (Clermont-Ferrand)

## 09h30 - 10h00 AMPHI CONGRÈS

### > Prix de Thèse – Ma Thèse en 180 secondes

- Modérateurs: Françoise STANKE-LABESQUE (Grenoble), Luc ZIMMER (Lyon)

- 09h30 Margaux LAFleurIE (Toulouse)
- 09h35 Thomas SOEIRO (Marseille)
- 09h40 Elise PAPE (Nancy)
- 09h45 Michael THY (Paris)
- 09h50 Sonia SAIB (Saint-Etienne)
- 09h55 Gaëlle HUGON (Orsay)

# PROGRAMME SCIENTIFIQUE

## 10h00 – 11h00 Happy Hour Posters (PM2)

atrium + hall d'accueil

### ZONE JAUNE

#### Neuropsychopharmacologie

Modérateurs : Julie DEGUIL (Lille),  
Guillaume HACHE (Marseille)

- PM2-001 - Updated prevalence of potentially inappropriate prescriptions in older adults in France (2017) - *Marie-Laure LAROCHE (Limoges)*
- PM2-002 - Assessment of alprazolam abuse: data from the French addictovigilance network - *Hélène PEYRIERE (Montpellier)*
- PM2-003 - Abuse and dependence potential of diazepam: Addictovigilance data - *Amélie DAVELUY (Bordeaux)*
- PM2-004 - First-line use and misuse of weak opioids: a repeated cross-sectional study between 2012 and 2018 in France - *Allison SINGIER (Bordeaux)*
- PM2-005 - Covid-19 vaccines and Guillain-Barré syndrome: a perspective from spontaneous report data - *Blandine BERTIN (Lille)*
- PM2-006 - Pharmacological inhibition of lysosomal glucocerebrosidase activity in experimental cellular models of Parkinson's disease - *Marie-Amandine BONTE (Lille)*

### ZONE VERTE

#### STP 2

Modérateurs : Nicolas GREGOIRE (Poitiers),  
Caroline MONCHAUD (Limoges)

- PM2-007 - Clinical pharmacokinetics and dose optimization of Cefiderocol in critically ill patients - *Noël ZAHR (Paris)*
- PM2-008 - Does inflammation impact tacrolimus metabolism in kidney transplant recipients? - *Florian LEMAITRE (Rennes)*
- PM2-009 - Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics - *Olivier LE TILLY (Tours)*
- PM2-010 - Evaluation of pharmacokinetic parameters of critically ill patients and simulation of dosing regimens required by Bayesian Therapeutic Drug Monitoring of fluconazole - *Elodie MATUSIK (Lille)*
- PM2-011 - Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy - *Michael THY (Paris)*
- PM2-012 - Is trough concentration the best pharmacokinetic parameter for real-world infliximab exposure evaluation? *Camille TRON (Rennes)*

**ZONE ROSE****Pharmacovigilance 2**

**Modératrices :** Bénédicte LEBRUN-VIGNES (Paris),  
Aurélie GRANDVUILLEMEN (Dijon)

- PM2-013 - Antipsychotics and QT Prolongation:  
a Pharmacovigilance Study - Constance BORDET  
(Toulouse)
- PM2-014 - Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients - Dorine FOURNIER (Rennes)
- PM2-015 - Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis - Alex HLAVATY (Grenoble)
- PM2-016 - Calcitonin gene-related peptide antagonists and Raynaud's phenomenon: a potential safety signal - Alexandre O. GÉRARD (Nice)
- PM2-017 - Association between road traffic accidents and drugs belonging to the antiepileptic labelled class: a pharmacovigilance analysis in VigiBase® - Véronique LELONG-BOULOUARD (Caen)
- PM2-018 - Drug-associated sleep-related eating disorder: a disproportionality analysis - Diane MERINO (Nice)
- PM2-036 - Risk factors associated with immune checkpoint inhibitors-induced nephropathy: a case-control study - Alexandre O. GÉRARD (Nice)

**ZONE GRISE****Addictovigilance 2**

**Modératrices :** Amélie DAVELUY (Bordeaux),  
Marie GERARDIN (Nantes)

- PM2-019 - Complications-related to nitrous oxide abuse: case-series reported to Occitanie-Est addictovigilance centre - Céline EIDEN (Montpellier)
- PM2-020 - Worrying increase of serious health complications and deaths related to methadone and cocaine co consumption: a thirteen years of Methadone post marketing surveillance by French addictovigilance network - Elisabeth FRAUGER (Marseille)
- PM2-021 - Is oxazepam different from other benzodiazepines? Results of the first addictovigilance evaluation - Marylène GUERLAIS (Nantes)
- PM2-022 - Nitrous oxide: from the emergence of an addictovigilance signal to a major public health problem - Marylène GUERLAIS (Nantes)
- PM2-023 - Gabapentinoid misuse: what users think, what prescribers suspect? Camille PONTÉ (Toulouse)

# PROGRAMME SCIENTIFIQUE

## 10h00 – 11h00 Happy Hour Posters (PM2)

atrium + hall d'accueil

ZONE BLEUE Covid	ZONE VIOLETTE Pharmaco-épidémiologie
<p>Modérateurs: Vincent RICHARD (Rouen), Aymeric LANORE (Suresnes)</p> <ul style="list-style-type: none"><li>▪ PM2-024 - Impact of anti-covid-19 vaccination on arterial hypertension: an observational study based on pharmacovigilance cases from the Auvergne-Rhone-Alpes region - Marlène DAMIN-PERNIK (Saint-Etienne)</li><li>▪ PM2-025 - Is transient global amnesia an adverse event associated with COVID-19 vaccines? Diane MERINO (Nice)</li><li>▪ PM2-026 - Deaths induced by compassionate hydroxychloroquine administration during first COVID-19 wave: an estimate - Alexiane PRADELLE (Villeurbanne)</li><li>▪ PM2-027 - Ensuring quality control in a clinical trial during the COVID-19 pandemic: the experience of the Inserm C20-15 DisCoVeRy study in France - Claire FOUGEROU-LEURENT (Rennes)</li><li>▪ PM2-028 - Risk of herpes zoster reactivation after covid-19 vaccination: - Hazel RICHARD (Caen)</li><li>▪ PM2-029 - Myocarditis after mRNA COVID-19 vaccines. A comparative analysis using French Spontaneous Reporting Data - Francesco SALVO (Bordeaux)</li></ul>	<p>Modérateurs: Jean-Luc FAILLIE (Montpellier), Johana BENE (Lille)</p> <ul style="list-style-type: none"><li>▪ PM2-030 - Does statin use increase the risk of adrenal insufficiency? Pernelle NOIZE (Bordeaux)</li><li>▪ PM2-031 - Risk of skin ulcer and use of COX-2 inhibitors: a national population-based nested case control study - Justine PEREZ (Grenoble)</li><li>▪ PM2-032 - A new tool to study effects of antenatal medication exposure on severe neurodevelopmental disorders in childhood: feasibility study in Haute-Garonne - Caroline HURAUT-DELARUE (Toulouse)</li><li>▪ PM2-033 - Lack of transparency, poor reporting and overinterpretation of disproportionality analyses for signal detection in pharmacovigilance databases - Charles KHOURI (Grenoble)</li><li>▪ PM2-034 - Diuretic prescribing cascade with gabapentinoid use among a national cohort of older adults - Bérenger LARGEAU (Tours)</li><li>▪ PM2-035 - Factors associated with the concomitant exposure to statins and macrolides at risk of interaction - a cohort study based on the French healthcare insurance database - Ana-Maria VILCU (Paris)</li></ul>

## 11h00 - 12h30 AMPHI A

### > Thème transversal 1: Nouvelles approches / interventions dans les hémopathies malignes

- Modérateurs: Samia MOURAH (Paris), Fabien DESPAS (Toulouse)

#### Conférences invitées

- 11h00 Les défis de la découverte de nouveaux médicaments en onco-hématologie - Lina BENAJIBA (Paris)
- 11h30 CAR-T cell: de la fabrication à l'utilisation - Ibrahim YAKOUB-AGHA (Lille)
- 12h00 Evaluation de la balance bénéfice / risque - Vincent LEVY (Paris)

## 11h00 - 12h30 AMPHI CONGRÈS

### > Débat / table ronde: Nouvelles procédures accélérées de mise sur le marché des médicaments, prise de risque ou progrès?

- Modérateurs : Dominique DEPLANQUE (Lille), Tabassome SIMON (Paris)

#### Conférences invitées

11h00 Bénéfices et risques des procédures accélérées - Matthieu ROUSTIT (Grenoble)

11h30 La position de l'ANSM - Valérie DENUX (Paris)

12h00 L'expérience américaine - Michel CUCHERAT (Lille)

## 12h45 – 13h45 AMPHI A

### > Symposium PROMISE PROTEOMICS: Suivi thérapeutique pharmacologique des anticorps monoclonaux thérapeutiques : apports de la spectrométrie de masse



- Modératrice : Camille TRON (Rennes)

- Suivi thérapeutique pharmacologique des anticorps monoclonaux thérapeutiques en spectrométrie de masse : de la preuve de concept à l'adaptation posologique personnalisée. Françoise STANKE-LABESQUE (Grenoble)

- Suivi thérapeutique pharmacologique des immunothérapies : quelles perspectives pour la spectrométrie de masse ? Benoit BLANCHET (Paris)

## 12h45 – 13h45 AMPHI CONGRÈS

### > Symposium PFIZER: Stratégie thérapeutique anti-SARS-CoV-2 chez les patients à risque et les populations particulières



- Modérateur : Florian LEMAITRE (Rennes)

- Stratégie thérapeutique antivirale chez les patients à risque – Anne GOFFARD (Lille)

- Populations particulières et associations de médicaments avec le nirmatrelvir/ritonavir : application des recommandations thérapeutiques de la SFPT – Florian LEMAITRE, coordinateur de la rédaction des recommandations (Rennes)

# PROGRAMME SCIENTIFIQUE

## 14h00 - 15h30 AMPHI CONGRÈS

### Thème transversal 2: Pharmacologie des troubles cognitifs

- Modérateurs: Joelle MICALLEF (Marseille), Kamel MASMOUDI (Amiens)

#### Conférences invitées

- 14h00 Aspects cliniques et approches pharmacologiques des troubles cognitifs : enjeux, limites et perspectives - Régis BORDET (Lille)
- 14h30 Troubles cognitifs : rôle inducteur des médicaments et des substances - Michel MALLARET (Grenoble)
- 15h00 Exploration par neuroimagerie des voies physiopathologiques des troubles cognitifs - Luc ZIMMER (Lyon)

## 15h30 – 16h00

### > Pause café – Rendez-vous e-posters simples (PS)

## 16h00 - 17h30 AMPHI CONGRÈS

### > Thème transversal 2: Pharmacologie des troubles cognitifs

- Modérateurs: Olivier BLIN (Marseille), Elisabeth POLARD (Rennes)

#### Conférences invitées

- 16h00 Nouvelles avancées dans les biomarqueurs EEG des fonctions cognitives chez l'homme - Thibaut DONDAIN (Lille)
- 16h30 Les médicaments à visée vasculaires et métaboliques: un avenir pour la prise en charge des troubles cognitifs - Didier LEYS (Lille)
- 17h00 Y-a-t-il besoin d'approches pharmacologiques spécifiques pour les troubles cognitifs en psychiatrie – Pierre-Michel LLORCA (Clermont-Ferrand)

## 17h30 – 18h30 AMPHI A

### > STP, Modélisation- Bioéquivalence et variabilité: un nouveau chapitre ?

- Modérateur: Pierre MARQUET (Limoges)
- Intervenants: Philippe LECHAT (Paris), Didier CONCORDET (Toulouse)

## 17h30 – 18h30 SALLE DES THÈSES

### > Communications libres – Thème Covid

- Modérateurs: Mathieu MOLIMARD (Bordeaux), Jean-Luc CRACOWSKI (Grenoble)

#### Communications libres

17h30	CO-049 - Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study - Renaud FELTEN (Strasbourg)
17h40	CO-050 - Impact of lockdown in COVID-19 on methadone-use related hospitalizations in France - Justine PERINO (Bordeaux)
17h50	CO-051 - Drug safety in patients treated for COVID-19: a french pharmacovigilance survey - Aurélie GRANDVUILLEMIN (Dijon)
18h00	CO-052 - Increase of overdose and deaths related to methadone during COVID-19 epidemic - Elisabeth FRAUGER (Marseille)
18h10	CO-053 - Recurrence of adverse events of special interest after COVID-19 vaccines rechallenge: a Vigibase® study - Marion LEPELLEY (Grenoble)
18h20	CO-054 - Adenovirus-vectored vaccines and Guillain-Barré syndrome: an observed to expected analysis from cases recorded in the French Pharmacovigilance Database - Marina ATZENHOFFER (Lille)

## 17h30 – 18h30 AMPHI CONGRÈS

### > Table ronde - Pharmacologues, cliniciens, patients, médias : tous ensembles, lanceurs d'alerte

- Modérateur: Bernard BEGAUD (Bordeaux)
- Intervenants: Sandrine CABUT (Journaliste, Le Monde), Joelle MICALLEF (Marseille), Valérie LETARD (sénatrice du Nord, vice-présidente du Sénat), Juriste à confirmer

## 17h30 – 18h30 L'ANTRE 2 - 1 bis Rue Georges Lefebvre, 59000 LILLE

### > Conférence Grand Public : Activité physique : protéger ses artères pour protéger son cœur et son cerveau

- Intervenants: Elsa HEYMAN (Lille), Patrice DEGRAEFF (Lille)

## 19h30

### > Soirée du congrès (sur inscription)

SALLE KINO, Domaine Universitaire Pont de Bois à Villeneuve-d'Ascq

# PROGRAMME SCIENTIFIQUE

## JEUDI 16 JUIN

**09h00 – 10h30 AMPHI A**

### Thème transversal 4 – Pharmacologie de la ferroptose

- Modérateurs: David DEVOS (Lille), Luc ZIMMER (Lille)

#### Conférences invitées

- 09h00 The different types of cell death: ferroptosis, myth or reality?  
Implications for cancer - Bettina PRONETH, EPHAR lecture (Munich, Allemagne)  
09h30 Ferroptosis and central nervous system - David DEVOS (Lille)  
10h00 Ferroptosis and pharmacological modulation - James DUCE (Cambridge, UK)

**09h00 – 10h30 SALLE DES THÈSES**

### Communications libres – Thème STP

- Modérateurs: Romain GUILHAUMOU (Marseille), François STANKE-LABESQUE (Grenoble)

#### Communications libres

- 09h00 CO-055 - A machine learning approach to predict vancomycin exposure after intermittent infusion - Jean-Baptiste WOILLARD (Limoges)  
09h10 CO-056 - Clinical impact of early intra-individual variability of tacrolimus trough concentrations after renal transplantation: preliminary results of the VIPATIA study - Florian LEMAITRE (Rennes)  
09h20 CO-057 - Association between CYP2D6 genotype and venlafaxine and O-desmethylvenlafaxine concentrations and efficacy: results from two french studies - Céline KONECKI (Le Kremlin-Bicêtre)  
09h30 CO-058 - Amoxicillin-induced neurotoxicity: contribution of a data warehouse to the determination of a toxic concentrations threshold - Sébastien LALANNE (Rennes)  
09h40 CO-059 - Real-time automation of UFH individualization therapy during extracorporeal circulation based on a robust K-PD model - Robin CHAUX (Saint-Etienne)  
09h50 CO-060 - Switch from intravenous to sub-cutaneous infliximab in inflammatory bowel disease: which consequences from a pharmacokinetic perspective? Camille TRON (Rennes)  
10h00 CO-061 - Influence of CYP2D6 phenotype on the Pharmacokinetics-Pharmacodynamics of tramadol - Soizic PERCEVAULT (Lille)  
10h10 CO-062 - Neurotoxicity of beta-lactams in critically ill patients, a prospective evaluation of the 2019 SFPT/SFAR published therapeutic concentration target ranges - Youssef BENNIS (Amiens)  
10h20 CO-063 - Development of a bayesian estimator for a recombinant factor VIII Fc fusion protein to personalize prophylaxis for patients with haemophilia A - Audrick GIBERT (Saint-Etienne)

## 09h00 – 10h30 AMPHI CONGRÈS

### Thème transversal 3 – Le médicament, un objet d'interactions

- Modérateurs: Béatrice SAINT-SALVI (Saint-Denis), Bertrand DECAUDIN (Lille)

#### Conférences invitées

Le point de vue français :

- Les attentes du pharmacien clinicien - Pierrick BEDOUCH (Grenoble)
- Les attentes du pharmacologue médical - Sophie GAUTIER (Lille)
- Les attentes du thérapeute - Stéphane MOULY (Paris)

Le point de vue européen :

- Pierre MARQUET (Limoges)

## 10h30 – 11h00 Pause café

## 11h00 – 12h00 AMPHI CONGRÈS

### Assemblée Générale de la SFPT et Remise des prix

## 12h00 – 12h30 Déjeuner

## 12h30 – 15h30 SALLES PRÉSAGE

Atelier DPC n° 65952200002 (sur inscription)

### Chambre des erreurs : améliorer la qualité et la sécurité des soins et du patient par la mise en situation

- Formateurs: Sophie GAUTIER (Lille), Marc LAMBERT (Lille)

## 12h30 – 15h30 SALLE 4

Atelier DPC n° 65952200001 (sur inscription)

### Bon usage des psychotropes : comment optimiser la prescription

- Formateurs: Caroline VICTORRI-VIGNEAU (Nantes), François MONTASTRUC (Toulouse), Florian NAUDET (Rennes)

## 12h30 – 15h30 AMPHI A

Atelier sur inscription

### Session validant la formation continue en expérimentation animale : exploration comportementale et neuroimagerie

- Formateurs: Julie DEGUIL (Lille), Florent AUGER (Lille)

# LISTE DES E-POSTERS

## RETRouvez TOUS LES E-POSTERS SIMPLES (PS) DANS L'APPLI MOBILE DU CONGRÈS !

- PS-001 - Designing dedicated rapamycin nanoparticles for articular vectorization: a holistic pharmacological approach - Elise PAPE (Nancy)
- PS-002 - Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy - Michael THY (Paris)
- PS-003 - Predictive in-vitro approach for assessing drug transporter modulation during inflammation - Sonia SAIB (Saint-Etienne)
- PS-004 - Quantitative monitoring of enhanced blood-brain barrier permeability induced by focused ultrasound using 18F-FDS PET imaging - Nicolas TOURNIER (Orsay)
- PS-005 - Osteonecrosis of the jaw during axitinib exposure: a case report - Brahim AZZOUZ (Reims)
- PS-006 - Use of cardiovascular and antidiabetic drugs during COVID19 epidemic in France - Clément MATHIEU (Bordeaux)
- PS-007 - Fatal acute respiratory distress syndrome with abatacept in a rheumatoid arthritis patient - Julien MAHE (Nantes)
- PS-008 - Impact of pharmacovigilance in the management of risk related to medication errors: assessment of a working group at Nantes University Hospital - Julien MAHE (Nantes)
- PS-009 - Hospitalizations after substance use in a University Hospital during the COVID-19 pandemic - Justine PERINO (Bordeaux)
- PS-010 - Adverse drug reactions to apomorphine: a worldwide pharmacovigilance database analysis - Claire LE CORRE (Rennes)
- PS-011 - Deprescribing antihypertensive drugs after starting OSA primary therapy? Bruno REVOL (Grenoble)
- PS-012 - Feasibility of Objective and Structured Clinical Examination in Pharmaco-Toxicology training - Marine AUFRRET (Lille)
- PS-013 - Anti-NMDA receptor encephalitis and COVID-19 vaccination? Thierry TRENQUE (Reims)
- PS-014 - Drug-drug interactions of protein kinase inhibitors in chronic myeloid leukemia patients: A study using the French health insurance database - Fabien DESPAS (Toulouse)
- PS-015 - Analysis of adverse drug reactions transmitted via the Continuum+ platform, the experience of the Rennes Pharmacovigilance center - Lucie-Marie SCAILTEUX (Rennes)
- PS-016 - Adverse reaction reporting and inquiries about Covid-19 vaccines from general practitioners - Jean-Luc FAILLIE (Montpellier)
- PS-017 - Adverse drug reactions associated with ivermectin use for COVID-19 reported in the WHO's pharmacovigilance database - Jean-Luc FAILLIE (Montpellier)
- PS-018 - Assessment of global DNA methylation in peripheral blood cell subpopulations of patients with axial spondyloarthritis: preliminary results - Eric TOUSSIROT (Besançon)
- PS-019 - Fractures reduction with osteoporotic treatments in patients over 75-year old: a systematic review and meta-analysis - Eric TOUSSIROT (Besançon)
- PS-020 - Potentially inappropriate medication use in pre-frail older adults - Marie-Laure LAROCHE (Limoges)
- PS-021 - Renal disease associated with injectable amoxicillin with or without clavulanic acid - Constance BORDET (Bordeaux)
- PS-022 - Effects of new quinazoline analogues on phosphodiesterase-5 activity and relaxation of rat isolated pulmonary arteries - Usana CHATTURONG (Besançon)
- PS-023 - Baclofen misuse: Analyse of 46 patients with non-medical use - Juliana LIMA-TOURNEBIZE (Nancy)
- PS-024 - NOX1 and NOX2: two enzymes that promote endothelial-to-mesenchymal transition induced by melanoma conditioned media - Diane LECHEVALIER (Angers)
- PS-026 - GLP-1 receptor agonists and the risk of thyroid cancer - Jean-Luc FAILLIE (Montpellier)
- PS-027 - Drug-induced bradykinin-mediated angioedema: analysis of Brittany cases from the National Pharmacovigilance Database - Greta GOURIER (Brest)
- PS-028 - Proton pump inhibitors induced lupus erythematosus: a disproportionality study using the French pharmacovigilance Database and VigiBase - Bénédicte LEBRUN-VIGNES (Paris)



- PS-029 - Parents' perceptions of determinants of their decision to enroll or not their infant in a clinical trial: a qualitative analysis - Tiphanie GINHOUX (Lille)
- PS-030 - Evaluation of the management of tramadol use disorder in patients hospitalized for withdrawal - Hélène PEYRIERE (Montpellier)
- PS-031 - Overview of literature monitoring practices of clinical trials vigilance units in french institutional sponsors – A study from the REVISE working group - Astrid PRIOUL (Rennes)
- PS-032 - Takotsubo syndrome in a chronic cannabis user: a case report - Emilie BOUQUET (Poitiers)
- PS-033 - Immune Checkpoint Inhibitors-induced transplant rejection: analysis of the world pharmacovigilance database - Alexandre O. GÉRARD (Nice)
- PS-034 - Medication errors involving infusion pump programming: a persistent never event - Louise GABORIAU (Lille)
- PS-035 - Simultaneous quantification of infliximab and adalimumab in human plasma by liquid chromatography-tandem mass spectrometry using ready-to-use kit and comparison with two ELISA methods - Camille TRON (Rennes)
- PS-036 - Adverse drug reactions via semen: a study from the Vigibase® database - Isabelle LACROIX (Toulouse)
- PS-037 - Systematic review on sex differences for drug use after stroke - Antoine PARIENTE (Bordeaux)
- PS-038 - Temporary or definitive suspensions of clinical trials upon notifications from the Clinical Trials Vigilance Unit of Rennes University Hospital - Cécile LEFEUVRE (Rennes)
- PS-039 - RESPIR'Nantes study : what about the safety ? Pauline VIOLEAU (Nantes)
- PS-040 - Non-steroidal anti-inflammatory drugs and infection : regional survey on the knowledge of pharmacists and students - Aurélie GRANDVUILLEMEN (Dijon)
- PS-041 - Dupilumab and cutaneous lymphoma: adverse drug reaction or atopic dermatitis course? Louise GABORIAU (Lille)
- PS-042 - New perspectives for the therapeutic drug monitoring of tacrolimus: quantification in volumetric DBS based on an automated extraction and LC-MS/MS analysis - Caroline MONCHAUD (Limoges)

- PS-043 - Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines - François MONTASTRUC (Memphis)
- PS-044 - Adverse drug reactions of oxetorone: study in the French Pharmacovigilance Database - Sylvine PINEL (Paris)
- PS-045 - Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database - Jean-Baptiste QUILICHINI (Toulouse)
- PS-046 - Sudden hearing loss and COVID-19 vaccine: a potential signal? Diane MERINO (Nice)
- PS-047 - Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns - François MONTASTRUC (Toulouse)
- PS-048 - COVID-19 vaccine-associated trigeminal neuralgia: analysis of the WHO safety database - Diane MERINO (Nice)
- PS-049 - Social Pharmacology : The Story of the Marseille Elixir and the King Louis XIV\* - François MONTASTRUC (Toulouse)
- PS-050 - Specificities of Pregabalin drug poisonings: experience of the Marseille Poison Center (2020-2021) - Romain TORRENTE (Marseille)
- PS-051 - Pediatric suicide attempts with toxic substances (including drugs): 3 months prospective experience of the Marseille poison control center - Julien REYNOARD (Marseille)
- PS-053 - Renal safety profile of tyrosine kinase inhibitors targeting BCR-ABL: a study from VigiBase®, the WHO global database of individual case safety reports - Morgane CELLIER (Angers)
- PS-054 - In vitro cytotoxic and pharmacological effects of rapamycin on human chondrocytes, synoviocytes, and bone mesenchymal stem cells - Elise PAPE (Nancy)
- PS-055 - Determination of chemical composition of Moroccan Nigella Sativa and In vivo exploration of the antidepressant effect of Nigella Fixed Oil in rats - Youness KADIL (Casablanca)
- PS-056 - External evaluation of population pharmacokinetic models of infliximab and application for Bayes-based dosing in the clinical setting - Céline KONECKI (Reims)
- PS-057 - The outcome of progestin-related meningiomas during MRI follow-up - Taghla AHMED-KHALIFA (Vandoeuvre-lès-Nancy)

# LISTE DES E-POSTERS

- PS-058 - Topical sertaconazole during pregnancy and risk of adverse pregnancy outcome and major congenital anomalies: comparative study in the EFEMERIS database - Isabelle LACROIX (Toulouse)
- PS-059 - Incidence of atrial fibrillation associated with anticancer drugs exposure in monotherapy: a safety meta-analysis of phase 2 and 3 clinical trials - Joachim ALEXANDRE (Caen)
- PS-060 - Overview of adverse drug reactions reporting through the governmental web-portal in the former region of Poitou-Charentes - Marion ALLOUCHERY (Poitiers)
- PS-061 - Extra-hematological toxicities of busulfan used in the conditioning for hematopoietic stem cell transplant at the hematology department of casablanca - Sara EL HOUDAIBI (Casablanca)
- PS-062 - BRAF and MEK inhibitors rechallenge after adverse event in patients with cancer: a pharmacovigilance cohort study - Charles DOLLADILLE (Caen)
- PS-063 - Exposure to integrase-inhibitor antiretroviral drugs during pregnancy and congenital abnormalities: a case/non-case study from the international pharmacovigilance database VigiBase® - Laura SAINT-LARY (Toulouse)
- PS-064 - An easy method for daily quantification of 12 antibiotics, including beta-lactams, linezolid, fluoroquinolones and clindamycin: comparison between triple-quadrupole-spectrometer and high-resolution-mass-spectrometer - Catherine FELIU (Reims)
- PS-065 - Validation and routine analysis of 11 antibiotics in plasma by liquid chromatography coupled to mass spectrometry (LC-MS/MS): sulfosalicylic acid coupled to 2D-LC-MS/MS proved to be a generic, straightforward and robust assay for therapeutic drug monitoring - Maeva PALAYER (Paris)
- PS-066 - Does drug-induced erythema multiforme exist? A French Pharmacovigilance Study - Bénédicte LEBRUN-VIGNES (Paris)
- PS-067 - Is spontaneous reporting of ADRs a way to funnel patients' discontent? The illustrating case of Levothyrox® - Milou-Daniel DRICI (Nice)
- PS-068 - Therapeutic drug monitoring of voriconazole in sputum - Julien WILS (Rouen)
- PS-069 - Lamotrigine in patients with bipolar disorders: how to adjust dosage depending on plasma concentrations? Margot CHOUCHANA (Paris)
- PS-070 - Whole transcriptomic improves therapeutic management of melanoma patients - Baptiste LOUVEAU (Paris)
- PS-071 - Comprehensive cancer genomic profiling ATLAS: a pharmacogenomics tool in routine practice - Fanélie JOUENNE (Paris)
- PS-072 - Neonatal hypotonia after in utero exposure to high dose of hydroxychloroquine (HCQ)? Tessa PIETRI (Marseille)
- PS-073 - Ondansetron and blindness: an overlooked side effect - Romain BARUS (Lille)
- PS-074 - Contribution of voriconazole phenotyping to patient management - Christelle BOGLIONE-KERRIEN (Rennes)
- PS-075 - Determinants of the acceptability of dual oral therapy in the case of switch among HIV patients and doctors in France (PROBI study) - Anne-Sophie PETIT (Paris)
- PS-076 - Ceftazidime-avibactam stability in 2 portable diffusers - Sarah BAKLOUTI (Toulouse)
- PS-077 - Impact on memory of chronic and acute intoxication with diazepam and/or ethanol: from rodent models - Louise CARTON (Lille)
- PS-078 - Endocrine toxicities of immune checkpoint inhibitors: what differs from other immune-related adverse events. - Anne-Lise LECOQ (Le Kremlin-Bicêtre)
- PS-079 - mRNA Covid-19 vaccine and IgA nephropathy: analysis of French pharmacovigilance database and literature - Marlène DAMIN-PERNIK (Saint-Etienne)
- PS-080 - Clinical trials submission for authorization (CTSA) to french competent authorities: a four-year-retrospective-analysis of frequent questions impacting the CT safety - Simon KORNER (Lille)
- PS-081 - Anti-inflammatory drugs during pregnancy: pregnant women's awareness of their potential harm - Cyril LEVEN (Brest)
- PS-083 - Adverse event management in clinical trials by different vigilance structures in Civil Hospitals of Lille (HCL) - Clara GOLDBRONN (Lille)
- PS-084 - Exchanges between clinical trial vigilance and CRPV through adverse event reporting - Mélanie MOLTENIS (Besançon)



- PS-086 - Population pharmacokinetics of amikacin in patients on veno-arterial extracorporeal membrane oxygenation - Claire PRESSIAT (Créteil)
- PS-087 - Drug interaction between cannabidiol and clobazam: case(s) for concern? Camille POTEY (Lille)
- PS-088 - Induction of gout attacks by the multi protein kinase inhibitor drug nintedanib: a case report and disproportionality analysis in Vigibase® - Marion SASSIER (Caen)
- PS-089 - Peripheral neuropathies after BRAF and/or MEK inhibitors treatment: a pharmacovigilance study - Kevin BIHAN (Paris)
- PS-090 - Oral delivered-nicotine addiction in a patient with long-standing smoking cessation: the role of a nicotinic genetic polymorphism - Farid BENZEROUK (Reims)
- PS-091 - Incident users of protein kinase inhibitors in chronic myeloid leukemia: analysis of anticancer treatment courses and co-medications - A French population-based study using the French national health data system - Fabien DESPAS (Toulouse)
- PS-092 - Analysis of the impact of a safety measure on systemic (fluoro)quinolones prescriptions and dispensing and on reported adverse reactions in France - Basile CHRETIEN (Caen)
- PS-093 - Original initiative and feedback on the positive impact of a Patient Education workshop set up and coordinated by pharmacists for elderly type 2 diabetes patients and their caregivers - Claire DEMIOT (Limoges)
- PS-094 - Relationship between plasmatic metformin concentration and renal replacement therapy: a multi-center cohort study - Manon LAUNAY (Saint-Étienne)
- PS-095 - Stability of beta-lactams antibiotics in whole blood - Christelle BOGLIONE-KERRIEN (Rennes)
- PS-096 - Transcultural validation of a French-European version of the Prescription Opioid Misuse Index Scale : POMI-5F - Noémie DELAGE (Clermont-Ferrand)
- PS-097 - Real-life evaluation of drug interaction between tacrolimus and amlodipine - Aurelien COUETTE (Rennes)
- PS-098 - Covid-vaccines associated chilblains: analysis of the reports in VigiBase® - Basile CHRÉTIEN (Caen)
- PS-099 - Forged drug prescriptions: monitoring system in Auvergne Rhône-Alpes (AuRA) region and contribution to the national survey OSIAP - Alexandra BOUCHER (Lille)
- PS-100 - Zolpidem and zopiclone: time passes, measures changes but they remain false twins! - Aurélie AQUIZERATE (Nantes)
- PS-101 - Parkinson's disease progression in a patient with multiple myeloma treated with ixazomib - Pierre ROCANIÈRES (Montpellier)
- PS-102 - Impact of cannabinoid type 2 receptor selective agonist JWH133 on chronic kidney disease-induced cognitive impairment in rats - Guillaume HACHE (Marseille)
- PS-103 - Therapeutic drug monitoring of ruxolitinib in graft versus host disease in pediatric allogenic hematopoietic stem cell transplant recipients: a multicenter retrospective study - Camille TRON (Rennes)
- PS-104 - Proteomic profiling to identify markers of methotrexate resistance in rheumatoid arthritis - Jean ESCAL (Saint-Etienne)
- PS-105 - Increased risk of depression and suicidal behavior reporting associated with bictegravir - Laure-Hélène PRÉTA (Paris)
- PS-106 - Decreased oxygen saturation observed after nasal esketamine administration: report of two cases - Pascale PALASSIN (Montpellier)
- PS-107 - Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a pharmacovigilance study - Pascale PALASSIN (Montpellier)
- PS-108 - Adsorption of caspofungin in STX® filter used in continuous hemodiafiltration. Increasing the dose does not balance absorption. An in vitro study of the unbound fraction of caspofungin - Frédéric BAUD (Paris)
- PS-109 - Related muscle toxicity with concurrent use of tafamidis and rosuvastatine: which mechanism? Cosette LE SOUDER (Montpellier)
- PS-110 - Clinical course and prognosis of immune checkpoint inhibitors-induced myocarditis: a case series - Pascale PALASSIN (Montpellier)
- PS-111 - Inhaled antiasthmatic drugs and the risk of dental caries in children: a pharmacovigilance analysis - Alexandra HENRY (Paris)

# LISTE DES E-POSTERS

- PS-112 - Gilteritinib CSF distribution in a relapsing meningeal acute myeloid leukaemia FLT3-ITD+ patient - Lauriane GOLDWIRT (Paris)
- PS-113 - Medication errors in malaria management in children in Democratic Republic of Congo - Mireille NGALE (Kinshasa)
- PS-114 - A case report of interaction between ramipril and LDL-apheresis - Aurore MOREL (Reims)
- PS-115 - Outcome of mother and child after exposure to nivolumab during pregnancy: about a case - Cosette LE SOUDER (Montpellier)
- PS-116 - Pulmonary hypertension and immune checkpoint inhibitors - Pascale PALASSIN (Montpellier)
- PS-117 - Use of psychoactive substances associated with stress in the upper socio-professional categories - Louise CARTON (Lille)
- PS-118 - Two cases of COVID vaccine-induced immune thrombotic thrombocytopenia in Luxembourg - Nadine PETITPAIN (Vandoeuvre-lès-Nancy)
- PS-119 - Digital necrosis after cisplatin and pegfilgrastim treatment: a case report - Pascale PALASSIN (Montpellier)
- PS-120 - Pegfilgrastim-induced tumor lysis-like syndrome: a case-report and review of the World-Health-Organisation pharmacovigilance database VigiBase - Cosette LE SOUDER (Montpellier)
- PS-121 - Iodine overload thyroid disorders in the context of embolization with Lipiodol® - Laurence LAGARCE (Angers)
- PS-122 - Daptomycin Therapeutic drug monitoring: evaluation of simplified sampling strategies for Bayesian AUC estimation - Vianney TULOUUP (Lille)
- PS-123 - Therapeutic Drug Monitoring of Antibiotics in Critically Ill Children: An Observational Study in a Pediatric Intensive Care Unit - Mehdi OUALHA (Paris)
- PS-124 - Cefepime Population Pharmacokinetics and Dosing Regimens Optimization in Pediatric Intensive Care Unit - Mehdi OUALHA (Paris)
- PS-125 - Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®) - Benjamin BATTEUX (Amiens)
- PS-126 - Exploration of the effect of the association of cholecalciferol and calcium channel blocker on memory

- impairment in an aged rat model of cognitive decline - Houda FILALI (Casablanca)
- PS-127 - COVID-19 vaccines associated vestibular disorders: a case series and disproportionality analysis in Vigibase® - Claire BERNARDEAU (Caen)
- PS-128 - Therapeutic drug monitoring of clozapine: interpretation using individual pharmacokinetic variability approaches - Sylvie QUARANTA (Marseille)
- PS-129 - Therapeutic education program for the elderly subject treated with a direct oral anticoagulant (DOA) - Augustine KAKOU (Abidjan)
- PS-130 - Profile of drugs used for prescription or not (self-medication) by medical students - Sita N'ZOUÉ KANGAH (Bouaké)
- PS-131 - Knowledge and prescription in the therapeutic education of the patient by the nursing staff : the case of pediatric and rheumatology departments - Augustine KAKOU (Abidjan)
- PS-132 - Pharmacokinetics of levosimendan in pediatric intensive care unit - Thomas DUFLOT (Rouen)
- PS-133 - Incidence of diabetes induced by anti-PD1 and anti-PDL1 immunotherapies at the Brest University Hospital since their marketing authorization - Sandra LESVEN (Brest)
- PS-134 - Mouse models of diabetes-related ulcers: a systematic review and network meta-analysis - Axel COUTURIER (Grenoble)
- PS-135 - Dyslipidaemia and cardiovascular risk in type 1 diabetics: a descriptive cross-sectional analysis - Alexandre DONDONNE (Liège)
- PS-136 - The IL-13-induced production of M2 chemokines by human lung macrophages is enhanced by PGE2 and resistant to phosphodiesterase 4 inhibition - Philippe DEVILLIER (Suresnes)
- PS-137 - Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database - Emilie SBIDIAN (Créteil)
- PS-138 - Risk of hospitalisation for serious colchicine intoxication after concomitant exposure to macrolides: a nationwide claims database study - Ana VILCU (Paris)

- PS-139 - Risk of hospitalisation for serious colchicine intoxication after concomitant exposure to pristinamycin: a nationwide claims database study - Ana VILCU (Paris)
- PS-140 - Immunologic Thrombopenia Purpura (ITP)- induced COVID-19 vaccines. A descriptive study using French Pharmacovigilance Database - French Reporters COMIRNATY\* (Toulouse, Marseille, Bordeaux And Strasbourg)
- PS-141 - Decoding the natriuretic-like peptide lebetin 2 molecular mechanism of action in cardiac ischemia using a computational approach - Hinda ALLAOUI (Tunis)
- PS-142 - SGLT2 inhibitors in type 2 diabetes, a systematic review and meta-analysis of cardiovascular outcome trials balancing their benefits against their risks - Guillaume GRENET (Lille)
- PS-145 - Antiplatelet and anticoagulant therapy during angioplasty procedures for atheromatous or fibromuscular dysplasia renal artery stenosis: a survey of practices in European Society of Hypertension Excellence Centres (ESH-EC) in France - Béatrice DULY- BOUHANICK (Toulouse)

# INFORMATIONS PRATIQUES



## ADRESSE DU CONGRÈS

### Faculté de Médecine

Pôle Recherche

1 Place de Verdun - 59000 Lille

## HORAIRES DU CONGRÈS

### Mardi 14 juin 2022

10h30 - 18h00 (accueil à partir de 10h00)

### Mercredi 15 juin 2022

08h30 - 18h30 (accueil à partir de 08h00)

### Jeudi 16 juin 2022

09h00 - 12h00 (accueil à partir de 08h30)





## RESTAURATION

Les pauses et déjeuners (lunch box) sont inclus dans le tarif d'inscription, et se tiendront dans le Hall principal et l'Atrium du mardi au jeudi.

## SOIRÉE DU CONGRÈS

La soirée se tiendra le **mercredi 15 juin** à partir de 19h30 à la salle Kino-Ciné, Domaine universitaire Pont de Bois à Villeneuve d'Ascq.

Début du spectacle à 19h45.

**Adresse : Le Kino-Ciné,  
Domaine Universitaire du Pont de Bois  
3a rue du Barreau  
59650 Villeneuve-d'Ascq**

### Accès depuis la Faculté :

- **Métro ligne 1 – Direction Cantons / Stade Pierre Mauroy – Arrêt Pont de Bois (30 minutes)**
- **En voiture :** environ 20 minutes / Parking gratuit
- **Tarif congressiste :** 55 € TTC
- **Tarif Jeune et Etudiant :** 25 € TTC

**Participation sur inscription sous réserve des places disponibles, les réservations ne pourront pas se faire sur place.**

## BADGE

Votre badge, attestation de présence et sacoche contenant les documents du congrès vous seront remis à votre arrivée à l'accueil. **Pour des raisons de sécurité, le port du badge est obligatoire pendant toute la durée du congrès.**

## ORATEURS


Les orateurs sont invités à se présenter dans la salle de conférence munis d'une clé USB afin de déposer leur présentation PowerPoint à l'opérateur présent en salle, au moins 2 heures avant le début de la session.

## APPLI DU CONGRÈS

Retrouvez la liste des participants, le programme ainsi que tous les posters modérés (PM1 & PM2) et tous les e-posters simples (PS) dans l'appli du congrès. Pour cela, il vous suffit de télécharger l'appli WHO IS GEORGES dans l'App store ou Google Play.


# PLAN DU PÔLE RECHERCHE

## REZ-DE-CHAUSSÉE (R0)





## 1<sup>er</sup> ÉTAGE (R1)



# NOTES



# NOTES

---





# REMERCIEMENTS

---

LA SFPT REMERCIE SES PARTENAIRES POUR L'INTÉRÊT  
ET LE SOUTIEN QU'ILS ONT APPORTÉS À CE CONGRÈS.





Rendez-vous en 2023!

# Theranexus



ALTHX  
EURONEXT  
GROWTH  
FR0013286259

## Laboratoire spécialiste du traitement des maladies neurologiques rares

Theranexus est une société biopharmaceutique innovante, issue du CEA et spécialisée dans le traitement des maladies neurologiques rares et pionnière dans le développement de candidats médicaments ciblant à la fois les neurones et les cellules gliales.

Theranexus dispose d'une plateforme unique d'identification de caractérisation de candidats médicaments de thérapie innovante dans le domaine des troubles neurologiques rares et d'un premier candidat médicament en développement clinique dans la maladie de Batten.

[theranexus.com](http://theranexus.com)

NewCap<sup>®</sup>



Société Française de  
Pharmacologie et de Thérapeutique